Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indoramin Increase Tops UK Rises In September

Pricewatch UK – September 2021

Executive Summary

Benign prostatic hyperplasia treatment indoramin topped the UK’s steepest generic price rises in September with an average price that more than trebled, according to the latest figures from WaveData.

You may also be interested in...



Differing Dynamics Demonstrated In UK As Duo Double In October

Two generics saw their average UK trade prices almost double in October for very different reasons, according to the latest pricing information from market researcher WaveData.

Timolol Tops UK Price Rises In August

Timolol eye drops saw their prices leap in August while sildenafil’s slide saw prices cut in half, according to the latest UK generics pricing figures from WaveData.

June Sees UK Ivabradine Prices More Than Treble

Ivabradine exhibited interesting pricing dynamics in the UK in June, with the average cost of the heart failure treatment more than trebling despite the lowest offer in the market remaining stable.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel